173 related articles for article (PubMed ID: 7718885)
1. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
3. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
[TBL] [Abstract][Full Text] [Related]
4. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
[TBL] [Abstract][Full Text] [Related]
5. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells.
Battelli MG; Buonamici L; Bolognesi A; Stirpe F
Hepatology; 1994 Oct; 20(4 Pt 1):940-7. PubMed ID: 7927236
[TBL] [Abstract][Full Text] [Related]
7. Recognition and killing of tumour cells expressing heat shock protein 65 kD with immunotoxins containing saporin.
Poccia F; Piselli P; Di Cesare S; Bach S; Colizzi V; Mattei M; Bolognesi A; Stirpe F
Br J Cancer; 1992 Sep; 66(3):427-32. PubMed ID: 1520580
[TBL] [Abstract][Full Text] [Related]
8. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
9. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
[TBL] [Abstract][Full Text] [Related]
10. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
Zhang M; Yao Z; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Janik J; Brechbiel MW; Waldmann TA
Blood; 2006 Jul; 108(2):705-10. PubMed ID: 16551968
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD30 immunotoxins with native and recombinant dianthin 30.
Bolognesi A; Tazzari PL; Legname G; Olivieri F; Modena D; Conte R; Stirpe F
Cancer Immunol Immunother; 1995 Feb; 40(2):109-14. PubMed ID: 7882380
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
Morland BJ; Barley J; Boehm D; Flavell SU; Ghaleb N; Kohler JA; Okayama K; Wilkins B; Flavell DJ
Br J Cancer; 1994 Feb; 69(2):279-85. PubMed ID: 7507691
[TBL] [Abstract][Full Text] [Related]
13. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
[TBL] [Abstract][Full Text] [Related]
15. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
[TBL] [Abstract][Full Text] [Related]
17. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
[TBL] [Abstract][Full Text] [Related]
18. Hepatoxicity of ricin, saporin or a saporin immunotoxin: xanthine oxidase activity in rat liver and blood serum.
Battelli MG; Buonamici L; Polito L; Bolognesi A; Stirpe F
Virchows Arch; 1996 Feb; 427(5):529-35. PubMed ID: 8624583
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
Molavi O; Xiong XB; Douglas D; Kneteman N; Nagata S; Pastan I; Chu Q; Lavasanifar A; Lai R
Biomaterials; 2013 Nov; 34(34):8718-8725. PubMed ID: 23942212
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Casalini P; Dürkop H; Tazzari PL; Stein H; Stirpe F; Ferrini S
Br J Haematol; 1995 Jul; 90(3):572-7. PubMed ID: 7646996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
